Concepedia

Keith Orford

KO

25

Publications

2.7K

Citations

21

H-Index

1997

Active since

Affiliations

GlaxoSmithKline (United States)(Current)

The University of Texas MD Anderson Cancer Center

Memorial Sloan Kettering Cancer Center

Sarah Cannon

Massachusetts General Hospital

Keith Orford is an author at GlaxoSmithKline (United States) specializing in medicine, oncology, and cancer therapeutics.

Top concepts

Publications per year

1997–2022

25

Publications

25

Serine Phosphorylation-regulated Ubiquitination and Degradation of β-Catenin

Keith Orford, Caroline Crockett, Jane P. Jensen et al. · Journal of Biological Chemistry · 1997 · 707 citations · Full text

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in <i>BRAF</i> V600–Mutant Colorectal Cancer

Ryan B. Corcoran, Chloé E. Atreya, Gerald S. Falchook et al. · Journal of Clinical Oncology · 2015 · 501 citations · Full text

Exogenous Expression of β-Catenin Regulates Contact Inhibition, Anchorage-Independent Growth, Anoikis, and Radiation-Induced Cell Cycle Arrest

Keith Orford, Caroline C. Orford, Stephen W. Byers · The Journal of Cell Biology · 1999 · 275 citations · Full text

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Anthony W. Tolcher, Amita Patnaik, Kyriakos P. Papadopoulos et al. · Cancer Chemotherapy and Pharmacology · 2014 · 155 citations

, , +8

Differential H3K4 Methylation Identifies Developmentally Poised Hematopoietic Genes

Keith Orford, Peter V. Kharchenko, Weil Lai et al. · Developmental Cell · 2008 · 153 citations · Full text

, , +7

Rows per page

1–5 of 25